Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332788 | 1.00 | ERN1 (0.47) | ERN1PRKDCLMNACES2CES1 | |
| SCHEMBL14876998 | 0.82 | ERN1 (0.47) | ERN1PRKDCLMNACES2CES1 | |
| SCHEMBL1592418 | 0.82 | ERN1 (0.57) | ERN1PRKDCLMNAKDM4EALDH1A1 | |
| SCHEMBL29914869 | 0.79 | ERN1 (0.39) | ERN1PRKDCLMNAPTPN1 | |
| SCHEMBL3060245 | 0.79 | ERN1 (0.39) | ERN1PRKDCLMNAPTPN1 | |
| SCHEMBL931158 | 0.78 | ERN1 (0.64) | ERN1KDM4EALDH1A1 | |
| SCHEMBL31008305 | 0.78 | ERN1 (0.60) | ERN1PRKDCLMNAPTPN1 | |
| SCHEMBL8221595 | 0.78 | ERN1 (0.60) | ERN1PRKDCLMNAPTPN1 | |
| SCHEMBL1571069 | 0.78 | ERN1 (0.44) | ERN1PRKDCLMNA | |
| SCHEMBL12135681 | 0.78 | ERN1 (0.48) | ERN1PRKDCLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954793-A | Compounds as xanthine oxidase inhibitors and uses thereof | 广州市联瑞制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4486445-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | Centessa Pharmaceuticals (UK) Limited (GB) | 2025-01-08 | — | — | EP | disclosed |
| CN-119156375-A | Bicyclic heterocyclic derivatives and related uses | 森特萨制药(英国)有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-115135315-B | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2023167865-A1 | BICYCLIC-HETEROCYCLE DERIVATIVES AND RELATED USES | OREXIA THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | WO | disclosed |
| CN-116583502-A | Bicyclic-heterocyclic derivatives and their use as orexin-2 receptor agonists | 欧瑞夏治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |